CD20 is a transmembrane phosphoprotein located on the surface of B lymphocytes, mainly expressed in the pre-B cell to mature B cell stage. Anti-CD20 mAb exerts efficacy in killing B cell-derived tumors by antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and inhibition of cell growth (direct inhibition) by binding to… Continue Reading Progress in the development of new drugs for global hot targets: CD20 monoclonal antibody

  Once upon a time, bacterial infections claimed the lives of thousands of people. With the discovery and widespread clinical use of penicillin in the first half of the 20th century, antibiotics have greatly reduced the mortality caused by bacterial infections and made a great contribution to the health of… Continue Reading In the face of super bacteria, monoclonal antibody became the weapon of the post-antibiotic era

In April 23rd, the listing application of Heng Rui PD-1 monoclonal antibody Camrelizumab injection (SHR-1210) (CXSS1800009) was accepted by CDE. So far, 5 companies have applied for PD-1 mAb in China, and BMS’s Opdivo has been the first to receive priority assessment. The indications of the 5 companies were different.… Continue Reading HengRui pharmaceutical PD-1 mAb SHR-1210 is listed on the market